Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.

The efficiency of Proproten-100 containing antibodies to S100 protein in ultralow doses and used to relieve somatovegetative and psychoneurological manifestations of the alcohol withdrawal syndrome was studied in a double-blind, placebo-controlled clinical trial. The preparation possessed anxiolytic, sedative, hypnagogic, and vegetostabilizing properties. Proproten-100 more rapidly relieved the alcohol withdrawal syndrome than standard drugs (by 2 times).